rewirebio.iobenchmarks
Configuration

Exomiser v14 default, Talos 2026 comparison

SNV/indel prioritization in ACG trios with default Exomiser v14; rank limits assessed separately.

1 evaluation · 8 results

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

Model Capabilities & Hardware Requirements

Deployment facts recorded for Exomiser v14 default, Talos 2026 comparison. Fields the record does not carry are marked not recorded.

ParametersNot recorded
Minimum VRAMNot recorded
Inference LatencyNot recorded
Context WindowNot recorded
AccessNot recorded
LicenseNot recorded

Evaluations and results

1 evaluation · 8 results. Different protocols are not a single leaderboard.

Protocol: Exomiser rank-budget recovery in ACG trios · Dataset: ACG trios: Exomiser SNV/indel comparison as reported in Results

Sorted by Recall (rank: any) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.

Tested configurationRecall (rank: any)Top-1 accuracyTop-10 accuracyTop-5 accuracyCount (rank: any)Count (rank: top 1)Count (rank: top 10)Count (rank: top 5)
Exomiser v14 default, Talos 2026 comparisonEvaluation89%65%85%81%172127164157
All 8 result rows with coverage, uncertainty and sources
Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: Exomiser v14 default, Talos 2026 comparisonProtocol: Exomiser rank-budget recovery in ACG trios
Dataset: ACG trios: Exomiser SNV/indel comparison as reported in Results
172 Count (rank: any)
count · unknown

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Exomiser v14 ACG trio rank-budget evaluation

Not reported

Aggregation: Not reported

Automated reanalysis of genomic data for rare disease diagnostics at scale · Results, Comparison with other tools, rank all
Configuration: Exomiser v14 default, Talos 2026 comparisonProtocol: Exomiser rank-budget recovery in ACG trios
Dataset: ACG trios: Exomiser SNV/indel comparison as reported in Results
89% Recall (rank: any)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Exomiser v14 ACG trio rank-budget evaluation

Not reported

Aggregation: Not reported

Automated reanalysis of genomic data for rare disease diagnostics at scale · Results, Comparison with other tools, rank all
Configuration: Exomiser v14 default, Talos 2026 comparisonProtocol: Exomiser rank-budget recovery in ACG trios
Dataset: ACG trios: Exomiser SNV/indel comparison as reported in Results
127 Count (rank: top 1)
count · unknown

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Exomiser v14 ACG trio rank-budget evaluation

Not reported

Aggregation: Not reported

Automated reanalysis of genomic data for rare disease diagnostics at scale · Results, Comparison with other tools, rank top1
Configuration: Exomiser v14 default, Talos 2026 comparisonProtocol: Exomiser rank-budget recovery in ACG trios
Dataset: ACG trios: Exomiser SNV/indel comparison as reported in Results
65% Top-1 accuracy
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Exomiser v14 ACG trio rank-budget evaluation

Not reported

Aggregation: Not reported

Automated reanalysis of genomic data for rare disease diagnostics at scale · Results, Comparison with other tools, rank top1
Configuration: Exomiser v14 default, Talos 2026 comparisonProtocol: Exomiser rank-budget recovery in ACG trios
Dataset: ACG trios: Exomiser SNV/indel comparison as reported in Results
164 Count (rank: top 10)
count · unknown

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Exomiser v14 ACG trio rank-budget evaluation

Not reported

Aggregation: Not reported

Automated reanalysis of genomic data for rare disease diagnostics at scale · Results, Comparison with other tools, rank top10
Configuration: Exomiser v14 default, Talos 2026 comparisonProtocol: Exomiser rank-budget recovery in ACG trios
Dataset: ACG trios: Exomiser SNV/indel comparison as reported in Results
85% Top-10 accuracy
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Exomiser v14 ACG trio rank-budget evaluation

Not reported

Aggregation: Not reported

Automated reanalysis of genomic data for rare disease diagnostics at scale · Results, Comparison with other tools, rank top10
Configuration: Exomiser v14 default, Talos 2026 comparisonProtocol: Exomiser rank-budget recovery in ACG trios
Dataset: ACG trios: Exomiser SNV/indel comparison as reported in Results
157 Count (rank: top 5)
count · unknown

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Exomiser v14 ACG trio rank-budget evaluation

Not reported

Aggregation: Not reported

Automated reanalysis of genomic data for rare disease diagnostics at scale · Results, Comparison with other tools, rank top5
Configuration: Exomiser v14 default, Talos 2026 comparisonProtocol: Exomiser rank-budget recovery in ACG trios
Dataset: ACG trios: Exomiser SNV/indel comparison as reported in Results
81% Top-5 accuracy
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Exomiser v14 ACG trio rank-budget evaluation

Not reported

Aggregation: Not reported

Automated reanalysis of genomic data for rare disease diagnostics at scale · Results, Comparison with other tools, rank top5

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Use this configuration

How it works, versions and access

Related profile: Exomiser. This page retains the exact record and its evaluation context.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

3 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Facets: method types
1 values
  • conventional_pipeline
Individual claims
Evaluation of phenotype-driven gene prioritization methods for Mendelian diseases

Original source ↗

Other Exomiser configurations; Yuan et al. 2022 Table 2 classes Exomiser by phenotype comparison

Shared locator for this statement’s cited sources; not a separate locator for each citation.

Version: Briefings in Bioinformatics 23(2):bbac019, published 2022-02-04; PMC8921623 full-text XML
Retrieved: 2026-10-09T21:18:05Z

conflicting claim

["automated-source-review"] · 2026-10-12

Audit details

Correct the method type from none to conventional_pipeline (use-case baseline review 2026-10-12, table 2). Evidence from docs/reviews/use-cases/baselines-2026-10-12.md. Independent review 2026-10-12: approved. See docs/reviews/2026-10-12-method-type-corrections.md.

Conflicting source claim: "[\"conventional_pipeline\"]". Claim record status: source_checked.

Field: facets.method_types

Claim: metadata-correction-tags-20261012-706a18ff979bdef437c2

Source artifact SHA-256: a0e15e5a113ecbc1c8a3b17072a4028c55ae53c09ba0677d6fdb7601cfc8f1ca

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Facets: method types
1 values
  • conventional_pipeline
Individual claims
Automated reanalysis of genomic data for rare disease diagnostics at scale

Original source ↗

Other Exomiser configurations; Yuan et al. 2022 Table 2 classes Exomiser by phenotype comparison

Shared locator for this statement’s cited sources; not a separate locator for each citation.

Version: Nature Medicine 2026 final publication, 24 June 2026
Retrieved: 2026-09-30T21:24:16Z

conflicting claim

["automated-source-review"] · 2026-10-12

Audit details

Correct the method type from none to conventional_pipeline (use-case baseline review 2026-10-12, table 2). Evidence from docs/reviews/use-cases/baselines-2026-10-12.md. Independent review 2026-10-12: approved. See docs/reviews/2026-10-12-method-type-corrections.md.

Conflicting source claim: "[\"conventional_pipeline\"]". Claim record status: source_checked.

Field: facets.method_types

Claim: metadata-correction-tags-20261012-706a18ff979bdef437c2

Source artifact SHA-256: 629b9578ac42717245256feca69dc9c9d5442deb7d282dd1bdc5a6c1a1efd2ec

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Relationship: configuration of
uc-clinical-20260930-method-exomiser
Individual claims
Automated reanalysis of genomic data for rare disease diagnostics at scale

Original source ↗

Comparison with other tools; Methods

Version: Nature Medicine 2026 final publication, 24 June 2026
Retrieved: 2026-09-30T21:24:16Z

source checked

["automated-source-review"] · 2026-09-30

Audit details

Transcription from inspected primary source. No execution, independent replication or human scientific review.

Field: links:configuration_of:uc-clinical-20260930-method-exomiser

Claim: uc-clinical-20260930-association-exomiser-v14

Source artifact SHA-256: 629b9578ac42717245256feca69dc9c9d5442deb7d282dd1bdc5a6c1a1efd2ec

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID uc-clinical-20260930-exomiser-v14.

Related records

How to cite

Exomiser v14 default, Talos 2026 comparison. Rewire biological model benchmark database, release 2026-11-21-c8bea25e5abb. https://benchmarks.rewirebio.io/database/configuration/uc-clinical-20260930-exomiser-v14/

Release 2026-11-21-c8bea25e5abb. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.

The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence

Suggest a correction